Blueprint Medicines (BPMC)
(Delayed Data from NSDQ)
$103.34 USD
-1.08 (-1.03%)
Updated Jun 7, 2024 04:00 PM ET
After-Market: $103.33 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth D Momentum F VGM
Brokerage Reports
0 items in cart
Blueprint Medicines Corporation [BPMC]
Reports for Purchase
Showing records 461 - 480 ( 512 total )
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
BLU-554 Update Shows Favorable PFS and Promising Path for Treatment-Naive HCC
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
BLU-554 Updated ORR; Additional Details at ESMO, ILCA
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
MORNING CALL
Provider: WEDBUSH SECURITIES INC.
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
HEALTHCARE - 2017 PacGrow Healthcare Conference: Day 1 Recap
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q2 Financials; Multiple Data Releases on Tap, Next Up ?554 at ESMO
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of July 31
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Continued Good Data for BLU-285 in Advanced GIST; Likely Speedy Registration Path
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Week Ahead: Focus Calls
Provider: WEDBUSH SECURITIES INC.
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
ASCO 2017 Abstract Roundup and Schedule for Covered Companies
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q1 Financials; GIST Data Ahead at ASCO Likely to Inform Regulatory Strategy. Reiterate OUTPERFORM and Increasing PT to $55.
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of May 1
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
BLU-667 RET Study Enrollment Begins, AACR Landscape; Reiterate OUTPERFORM and Raising PT to $50
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of April 3
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of March 27
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of March 20
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Blueprint Medicines Corporation
Industry: Medical - Biomedical and Genetics
Q4 Financials; Expansion Cohorts on Track; Multiple Data Points in 2017, Reiterate OUTPERFORM and $43 PT
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D